Medical Developments International Ltd
ASX:MVP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medical Developments International Ltd
Revenue
Medical Developments International Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medical Developments International Ltd
ASX:MVP
|
Revenue
AU$40.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Revenue
AU$1.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$413m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$76.8m
|
CAGR 3-Years
69%
|
CAGR 5-Years
145%
|
CAGR 10-Years
44%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$93.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Medical Developments International Ltd
Glance View
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.
See Also
What is Medical Developments International Ltd's Revenue?
Revenue
40.6m
AUD
Based on the financial report for Dec 31, 2025, Medical Developments International Ltd's Revenue amounts to 40.6m AUD.
What is Medical Developments International Ltd's Revenue growth rate?
Revenue CAGR 10Y
13%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Medical Developments International Ltd have been 16% over the past three years , 11% over the past five years , and 13% over the past ten years .
